checkAd

     293  0 Kommentare Roche Annual General Meeting 2024 - Seite 2


    The following Board members standing for election were re-elected to the Remuneration Committee for a one-year term:

    • André Hoffmann
    • Dr Jörg Duschmalé
    • Anita Hauser
    • Professor Dr Richard P. Lifton 

    The Annual General Meeting appointed KPMG AG as statutory auditors for the 2024 financial year and Testaris AG as independent proxy until the conclusion of the 2025 Annual General Meeting.

    The address by Chairman of the Board of Directors Severin Schwan to shareholders will be available at https://www.roche.com/about/governance/annual-general-meetings.   

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Roche Holding AG Inhaber-Genussscheine!
    Long
    222,57€
    Basispreis
    1,63
    Ask
    × 14,00
    Hebel
    Short
    255,23€
    Basispreis
    2,04
    Ask
    × 11,69
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    About Roche
    Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with real-world data insights.

    In recognition of our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners.

    Genentech in the United States is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

    For more information, please visit www.roche.com.

    All trademarks used or mentioned in this release are protected by law.


    Roche Group Media Relations
    Phone: +41 61 688 888 / e-mail: media.relations@roche.com

    Hans Trees, PhD
    Phone: +41 79 407 72 58
    Nathalie Altermatt
    Phone: +41 79 771 05 25

    Simon Goldsborough
    Phone: +44 797 32 72 915
    Karsten Kleine
    Phone: +41 79 461 86 83

     
    Nina Mählitz
    Phone: +41 79 327 54 74
    Kirti Pandey
    Phone: +49 172 6367262

     
    Dr Rebekka Schnell
    Phone: +41 79 205 27 03
    Sileia Urech
    Phone: +41 79 935 81 48

    Attachment


    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Roche Annual General Meeting 2024 - Seite 2 All proposals of the Board of Directors approvedSeverin Schwan re-elected as Chairman of the Board of Directors; all other Board members standing for election confirmed37th consecutive dividend increase to CHF 9.60 per share Basel, 12 March 2024 – …

    Schreibe Deinen Kommentar

    Disclaimer